linjc16/ctgov huggingface dataset:
Prognostic Factors Affecting Recurrence and Disease-Free Survival After Surgical Resection for Cancer Rectum

Study Overview
=================
Brief Summary
-----------------
Tumor recurrence after curative surgical resection for rectal cancer is a serious complication that greatly affects the overall morbidity and the outcome. This study aims to identify the different prognostic factors affecting recurrence and disease-free survival after surgery.

Detailed Description
-----------------
A retrospective analysis of patients operated for cancer rectum with curative intent from. Exclusion criteria will include patients with familial adenomatous polyposis, multiple synchronous or metachronous rectal cancers, and death within 3 months. Incomplete patients' files and patients that lost follow-up will be excluded. Demographic, histopathological, follow up and outcome data will be collected from completed patients' files. Demographics include age, gender, family history, and chief complaint at the presentation. Histopathological data include tumor grade, vascular-perineural invasion, the total number of lymph nodes removed, and positive lymph nodes. Lymph node ratio will be defined as the ratio of positive lymph nodes to the total number of retrieved lymph nodes in a histopathology specimen. Disease-free survival will be calculated for each patient based on the time of surgery to the time of recurrence detection.

Official Title
-----------------
Predictors of Disease Free Survival After Curative Cancer Rectum Surgery

Conditions
-----------------
Rectal Cancer

Intervention / Treatment
-----------------
* Procedure: curative surgery for cancer rectum


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who had curative surgery for cancer rectum. Exclusion Criteria: Patients with familial adenomatous polyposis (FAP), multiple synchronous or metachronous rectal cancers, and death within 3 months Patients that lost follow-up will be excluded.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with cancer rectum underwent curative surgery<br>Patients with cancer rectum underwent curative surgery | Procedure: curative surgery for cancer rectum<br>* Curative surgery for cancer rectum.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Tumor recurrence | Presence of Tumor recurrence after curative surgery for cancer rectum. | Through study completion, an average of 3 year | 
| Disease free survival. | From date of surgery until the date of recurrence detection. | up to 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cancer rectum, recurrence, disease free survival
Characteristics of Renal Blood Flow in AKI Patients in ICU and Its Clinical Significance

Study Overview
=================
Brief Summary
-----------------
To study the changes in the renal artery and renal vein with renal cortical and medullary microcirculatory blood flow in patients with sepsis; to study the relationship between renal arteriolar and renal vein with renal cortical and medullary microcirculatory blood flow and renal function; and to find the value of ultrasonographic assessment of renal blood flow indices for evaluating prognosis in patients with sepsis.

Official Title
-----------------
Characteristics of Renal Blood Flow in AKI Patients With Sepsis and Its Clinical Significance

Conditions
-----------------
Acute Kidney Injury, Renal Artery Blood Flow, Renal Venous Return, Renal Microcirculation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age between 18-85 years old; Control group: patients with non-acute kidney injury after ICU general surgery; Observation group: patients who met the diagnostic criteria of AKI: Scr elevation ≥26.5 umol/L within 48h; Scr elevation exceeding 1.5 times and more than the basal value within 7d; and decrease in urine output (<0.5 ml/kg/h) with a duration of 6h or more. Exclusion Criteria: Those who did not meet the inclusion criteria or refused to be enrolled; patients with underlying end-stage renal disease or requiring long-term dialysis; renal transplant patients; patients with other underlying systemic diseases causing renal dysfunction (SCr > 88.4 umol/L); those who were unable to obtain a clear renal ultrasound view; those with suspected contrast allergy; those with pulmonary arterial systolic blood pressure ≥ 90 mm Hg; and those who were pregnant or breastfeeding women.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Acute kidney injury<br>Patients with acute injuries in ICU patients. | |
| Patients with non-acute kidney injury<br>ICU patients without acute injury patients. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 30-day major renal adverse events | Follow-up of patients with prognostic indicators of renal function within 30 days of enrolment, such as blood creatinine and the need for renal replacement therapy. | 30-day | 
| Renal artery blood flow | Ultrasound assessment of renal artery resistance index, and renal artery blood flow. | Day 1,Day 3,Day 5, Day 7 | 
| Renal venous return | Ultrasonographic assessment of renal venous reflux profiles. | Day 1,Day 3,Day 5, Day 7 | 
| renal microcirculation | Evaluation of renal microcirculation by ultrasonography. | Day 1,Day 3,Day 5, Day 7 |
TRANSPARK_LONG: The Diagnostic Value of Early Transcranial Ultrasound in Patients With Extrapyramidal Diseases in a Swedish Population

Study Overview
=================
Brief Summary
-----------------
Popular science summary of the project The purpose of the study is to investigate in a Swedish population how well the investigators' previous ultrasound findings match the final diagnosis (PD, APS or ET) after a particularly long follow-up time, which greatly increases the certainty that the diagnosis does not change more and is thus correct. Furthermore, the investigators want to study whether the initial ultrasound findings have changed during the control interval and whether measurement results regarding the diameter in one of the fluid-filled rooms in the brain (third ventricle) can be correlated with the development of cognitive impairment or dementia later in the course of the disease. For this, this study have got ethical permission to go into the patients' medical records and to call a subgroup back to the clinic to be able to do a new examination and a memory test.

Official Title
-----------------
TRANSPARK_LONG: The Diagnostic Value of Early Transcranial Ultrasound in Patients With Extrapyramidal Diseases in a Swedish Population: an Evaluation in the Form of a Retrospective Cohort Study With a Long Follow-up Time

Conditions
-----------------
Parkinsonism, Tremor, Dementia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with parkinsonism or essential tremor who came into contact with our clinic before 2017 Satisfactory transcranial bone window Previous TU (clinical indication) Exclusion Criteria: No transcranial bone window

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with parkinsonism<br>Parkinsonism incl. tremor, parkinsons, atypical parkinsons | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation | Is hyperechogenicity of substantia nigra at mesencephal plane (measured bilaterally in mm2 by transcranial b-mode sonography correlated with a high percentage of patients with classical Parkinsons Disease in contrast to atypical parkinsonism patients? | over 7-10 yrs | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation | Is 3rd ventricle atrophy (measured in mm by b-mode transcranial sonography) correlated with a high % of demented patients in the cohort? | 7-10 (retrospective) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Transcranial ultrasound, Substantia nigra
Predictors of Health Service Utilizations Among Key Population in Washington DC

Study Overview
=================
Brief Summary
-----------------
The primary objective of the proposed study is to investigate how PrEP use might result in an increase in the utilization of health and social services offered at a local community-based organization.Our primary hypothesis is that we will observe higher utilization of sexual health (STI screenings), psychosocial health (psychotherapy, and substance use treatment) and other social services (emergency cash assistance, food pantry, transportation assistance, clothing,and housing resources) among PrEP users (LAI-PrEP or daily oral) compared to participants who are PrEP naïve over the 12-month follow-up period.

Official Title
-----------------
A Mixed Methods Study of the Association Between LAI PrEP Initiation and Adherence, and Utilization of Health and Social Support Services Among Key Populations in Washington DC

Conditions
-----------------
Pre-exposure Prophylaxis, HIV, Health Behavior

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age of 18 years or above; confirmed HIV-negative status; residence in the Washington, DC metropolitan area; one of the following PrEP profiles (PrEP naïve [no history of any PrEP use in the past] currently on daily oral PrEP or receiving LAI-PrEP). Exclusion Criteria: being younger than18 years of age being unable to speak and/or read English a reported residence outside of the defined Washington, DC metropolitan area being unable or unwilling to provide written informed consent being unable to comply with the requirements of the protocol (i.e. persons with mental health conditions, persons who are intoxicated or incoherent for other reasons) evidence of suspected hepatoxicity

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The rate of service utilization (sexual health, psychosocial health & other social services) over 12 months as a function of demographic characteristics, mental health, and substance use behavior. |  | Over 12 months |
Serum Magnesium Level in Type 2 Diabetes Mellitus

Study Overview
=================
Brief Summary
-----------------
Diabetes mellitus (DM) is a chronic metabolic disorder characterized by persistent hyperglycemia. It may be due to impaired insulin secretion, resistance to peripheral actions of insulin, or both . Chronic hyperglycemia in synergy with the other metabolic aberrations in patients with diabetes mellitus can cause damage to various organ systems, leading to the development of disabling and life-threatening health complications, most prominent of which are microvascular (retinopathy, nephropathy, and neuropathy) and macrovascular complications leading to a 2-fold to 4-fold increased risk of cardiovascular diseases Mg2+ deficiency is usually identified by the measurement of serum Mg2+ concentration. Hypomagnesemia is defined by a serum Mg2+ concentration < 0.75 mmol/L, but a deficiency due to low dietary intake in otherwise healthy people is uncommon. Although overt signs of clinical Mg2+ deficiency are not routinely recognized in the healthy population, relatively low Mg2+ intake and/or Mg2+ status have been shown to be associated with chronic diseases, including cardiovascular disease, T2DM, osteoporosis, pulmonary disease, depression, migraine headaches, inflammation, and cancer

Official Title
-----------------
Serum Magnesium Level in Type 2 Diabetes Mellitus

Conditions
-----------------
Diabetes Mellitus

Intervention / Treatment
-----------------
* Diagnostic Test: Magnesium


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: • Type 2 Diabetes Mellitus according to WHO criteria. Exclusion Criteria: • Renal failure patients. Type I DM patients. Acute pancreatitis. Hyperthyroidism. Hyperparathyroidism. Malignancies. Patients on loop/thiazide diuretics. Patients on Mg supplement. Patients on Mg containing antacids. Any other conditions causing low Mg levels were excluded from the study.

Ages Eligible for Study
-----------------
Minimum Age: 30 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| cases group<br> | Diagnostic Test: Magnesium<br>* The aim of the study is to evaluate serum Mg level in type 2 DM patients.<br>|
| control group<br> | Diagnostic Test: Magnesium<br>* The aim of the study is to evaluate serum Mg level in type 2 DM patients.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| magnesium perecentage | evaluate serum Mg level in type 2 DM patients. | 1 year |
Magnetic Resonance Fingerprinting for Preoperative Evaluation of Lymphovascular Space Invasion in Early Stage Cervical Cancer

Study Overview
=================
Brief Summary
-----------------
The aim of this observational prospective study is to investigate the role of Magnetic Resonance Fingerprinting in preoperative assessment of early cervical cancer

Official Title
-----------------
Magnetic Resonance Fingerprinting for Preoperative Evaluation of Lymphovascular Space Invasion in Early Stage Cervical Cancer

Conditions
-----------------
Cervical Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with biopsy-proven cervical cancer FIGO stage IA-IIA undergoing surgery; Women aged >18 years old; Signed Informed Consent. Exclusion Criteria: Concurrent malignancies at other sites; Previous history of neoplasm; Refusal to sign written informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Association between T1-, T2- and ADC-maps and LVSI status |  | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation between T1-, T2- and ADC-maps and DFS and OS |  | 3 years | 
| Correlation between Radiomics-based analysis and LVSI status and DFS and OS |  | 3 years |
A Phase I Study of QL1604 for Advanced Solid Tumors

Study Overview
=================
Brief Summary
-----------------
In this study, patients with advance solid tumors will be treated with QL1604 monotherapy.

Official Title
-----------------
A Phase I Clinical Study to Evaluate Safety、 Tolerability, and Pharmacokinetics of QL1604 for the Treatment of Advanced Solid Tumors - A Phase Ic Preliminary Efficacy Expansion Study

Conditions
-----------------
Advanced Solid Tumor

Intervention / Treatment
-----------------
* Drug: QL1604


Participation Criteria
=================
Eligibility Criteria
-----------------
Key Inclusion Criteria: 18-75 years; At least one measureable lesion as defined per RECIST Version (v) 1.1 Histologically or cytologically confirmed、failed to standard therapy or lack standard therapy(except immunotherapy) advanced solid tumors; for cervical cancer, only squamous carcinoma、adenocarcinoma、adenosquamous carcinoma could be enrolled； hepatocellular carcinoma could be enrolled by clinical diagnosis Adequate important organ function Key Exclusion Criteria: Active autoimmune disease orautoimmune disease history Meningeal metastasis,or brain metastasis( except asymptomatic brain metastasis, or symptomatic brain metastasis but stable for more than 4 weeks after treatment, and have stopped systemic hormone treatment (prednisone of > 10 mg/day or equivalent hormone) for more than 2 weeks) Known hypersensitivity to protein macromolecules, and/or any of QL1604 excipients Radiotherapy, chemotherapy, hormone therapy, surgery, targeted therapy within 4 weeks prior to study drug (for micromolecule targeted therapy, within 2 weeks) Active hepaititis B or C infection Both HBsAg and anti-HCV Ab positive

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: QL1604<br> | Drug: QL1604<br>* QL1604 3 mg/kg Q3W<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Objective response rate (ORR) | ORR is defined the percentage of the participants who have achieved complete response (CR) or partial response (PR) using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 after the initiation of study treatment. | up to 2 years |
Changes in Functional Movement Scores Associated With Multimodal Chiropractic Care: a Pilot Feasibility Study

Study Overview
=================
Brief Summary
-----------------
Emergency medical services (EMS) personnel are at high risk of injuries, often related to overexertion while lifting or carrying patients or equipment. They require a high level of functional fitness to operate safely and avoid injuries. The purpose of this pilot study was to explore feasibility and assess effects of multimodal chiropractic care on Functional Movement Screen (FMS) scores among EMS students.

Detailed Description
-----------------
EMS students at a local community college voluntarily completed baseline FMS testing. Those who obtained 14 or less, a sign of movement dysfunction, were recruited to participate in a study to evaluate effects of multimodal chiropractic care on FMS scores. Participants received multimodal chiropractic care with an emphasis on spinal manipulation and corrective exercise for up to 6 weeks.

Official Title
-----------------
Changes in Functional Movement Scores Associated With Multimodal Chiropractic Care: a Pilot Feasibility Study

Conditions
-----------------
Chiropractic

Intervention / Treatment
-----------------
* Other: multimodal chiropractic care


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: current healthy paramedic students; Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Interventional Model Description: single group pilot study to determine feasibility and potential effect size
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Pre-intervention and post-intervention FMS scores<br>multimodal chiropractic care with FMS scores assessed pre- and post-intervention | Other: multimodal chiropractic care<br>* functional movement score followed by intervention of multimodal chiropractic care including spinal/extremity manipulation and exercise recommendation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Functional movement screen score (FMS) |  | 6 weeks |
ALDH1A1 Expression in Invasive Mammary Carcinoma

Study Overview
=================
Brief Summary
-----------------
ALDH1A1 isozyme oxidizes Retinaldehyde to retinoic acid, which regulates the expression of the genes involved in tumor-initiating stem-like cells, thereby initiating tumor growth and resistance to drugs. Much emphasis has been focused on ALDH1A1 as a CSC marker. High expression of ALDH1A1 has been reported as a poor prognostic marker in several tumor types and is associated with poor patient outcomes .

Detailed Description
-----------------
Breast cancer is one of the most common cancers among women. it is a heterogenous disease. several factors affect the prognosis of breast cancer. CSCs markers are one of the emerging prognostic biomarkers. ALDH1A1 isozyme oxidizes Retinaldehyde to retinoic acid, which regulates the expression of the genes involved in tumor-initiating stem-like cells, thereby initiating tumor growth and resistance to drugs. Much emphasis has been focused on ALDH1A1 as a CSC marker. High expression of ALDH1A1 has been reported as a poor prognostic marker in several tumor types and is associated with poor patient outcomes .

Official Title
-----------------
ALDH1A1 as A Stem Cell Marker and Its Correlation With the Clinico-pathological Parameters in Invasive Mammary Carcinoma

Conditions
-----------------
Breast Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with invasive mammary carcinoma carcinoma and underwent surgery Exclusion Criteria: Cases received pre-operative chemotherapy or radiotherapy. Cases with insufficient clinical data.
Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| evaluate expression of ALDH1A1 in invasive mammary carcinoma | immunohistochemical study | 4 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
breast cancer, CSCs, ALDH1A1